SS Innovations International (NASDAQ: SSII) is building a significant position in telerobotic surgery as remote procedures gain traction globally, according to a recent MedTech Dive report. The article, "Telerobotic surgery is advancing around the world. Will the US embrace it?," examined the technology's development and the regulatory and infrastructure questions surrounding remote surgery, highlighting SS Innovations alongside larger medical-device companies and emerging robotics developers. For SS Innovations, the discussion comes as its SSi Mantra system accumulates experience in telesurgery, a field that is moving from isolated demonstrations toward broader clinical and regulatory development.
Dr. Sudhir Srivastava, founder and CEO of SS Innovations and a cardiac surgeon, told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness. This insight underscores the company's focus on advancing telerobotic capabilities, which could expand access to specialized surgical care in remote or underserved areas. As of September 28, 2026, the company reported 195 robotic telesurgeries using its SSi Mantra system, including cardiac procedures and long-distance operations. This milestone demonstrates the system's growing reliability and versatility in real-world clinical settings.
The company's installed base reached 244 SSi Mantra systems as of September 28, up 45% from the end of 2025, while cumulative procedures reached 14,503. This rapid adoption reflects increasing trust among healthcare providers and suggests that telerobotic surgery is gaining momentum. SSi Mantra has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad. These expansions indicate that the technology is not limited to developed markets but is also making inroads in emerging economies, where access to advanced surgical care may be limited.
SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand the system into additional international markets. Regulatory approvals in these major markets could significantly accelerate adoption and validate the safety and efficacy of the SSi Mantra system. The company's progress in telesurgery is detailed in its newsroom at https://ibn.fm/SSII, and further information about SS Innovations International is available at SS Innovations International (NASDAQ: SSII). The MedTech Dive article can be accessed at https://ibn.fm/4ZLvL, and the full release is available at www.newmediawire.com.
The implications of SS Innovations' advancements extend beyond the company itself. Telerobotic surgery has the potential to revolutionize healthcare delivery by enabling expert surgeons to perform procedures remotely, reducing travel burdens for patients and addressing disparities in access to specialized care. However, challenges remain, including ensuring low-latency communication networks, establishing regulatory frameworks, and building clinical evidence. SS Innovations' growing experience with telesurgery, including long-distance operations, provides valuable data that could inform these efforts. As the company pursues FDA clearance and CE marking, its progress will be closely watched by regulators, competitors, and healthcare providers alike. The outcomes could shape the future of surgical robotics and telemedicine, making SS Innovations a key player in this evolving landscape.
